Lieber Institute is a 501(c)(3) organization, classified under Medical Research (NTEE H48). Contributions are tax-deductible.
855 North Wolfe Street Suite 323, Baltimore, MD 21205-1503
Among the 4 scored medical research organizations in Baltimore, Lieber Institute holds 9.1 months of operating reserves (peer median 27.1 months), runs a typical yearly deficit of 15.3% (peers: surplus of 27.2%), and has grown spending 6.6% a year (peers: grown spending 2.1% a year).
In fiscal year 2023 it reported $28,903,115 in revenue and $31,448,930 in expenses, with contributions making up 90.3% of revenue.
The mission of the institute is to translate basic genetic and molecular mechanisms of schizophrenia and related developmental brain disorders into clinical advances that change the lives of affected individuals. It is catalyzing a new understanding of brain disease by linking advances in the construction and function of the human brain with the development of novel therapeutic strategies.
Largest programs · fiscal year 2023
Clinical sciences: The clinical science division investigates mechanisms of schizophrenia and related brain disorders in clinical studies and in biological material from clinical samples specifically ascertained, evaluated and managed by institute staff and through collaborations with johns hopkins university, the national institute of mental health (nimh), university of bari (italy), medical coll… Read more
Clinical sciences: The clinical science division investigates mechanisms of schizophrenia and related brain disorders in clinical studies and in biological material from clinical samples specifically ascertained, evaluated and managed by institute staff and through collaborations with johns hopkins university, the national institute of mental health (nimh), university of bari (italy), medical college of Virginia, morgan state university and others.
$4,645,870 spent · 17.7% of program spending
Basic sciences: The creation of model systems at the institute to study psychiatric illness is the major goal of the basic sciences research program. Using our unique collection of human brain material and induced pluripotent STEM cell lines, we are defining the molecular signature of disease risk. To provide the basis for therapeutic intervention we are developing new technologies using human STE… Read more
Basic sciences: The creation of model systems at the institute to study psychiatric illness is the major goal of the basic sciences research program. Using our unique collection of human brain material and induced pluripotent STEM cell lines, we are defining the molecular signature of disease risk. To provide the basis for therapeutic intervention we are developing new technologies using human STEM cells to identify the functional consequences of genetic risk factors. The goal of these studies is the identification of therapeutic targets based on the mechanisms of disease.
$16,070,140 spent · 61.1% of program spending
Drug discovery: Improved genetic understanding of diseases of brain development is revealing new drug discovery opportunities. Guided by genetics, the institute's drug discovery division is investigating new targets for psychiatric diseases, with the goal of validating innovative approaches that will lead to novel medicines for patients suffering from these conditions. The drug discovery division… Read more
Drug discovery: Improved genetic understanding of diseases of brain development is revealing new drug discovery opportunities. Guided by genetics, the institute's drug discovery division is investigating new targets for psychiatric diseases, with the goal of validating innovative approaches that will lead to novel medicines for patients suffering from these conditions. The drug discovery division maintains a state of the art medicinal chemistry laboratory and unique capabilities in target validation.
$5,588,288 spent · 21.2% of program spending
Where each dollar went · fiscal year 2023
Of every dollar it spent, 84¢ went to programs, 16¢ to management and 0¢ to fundraising.
Programs $26,304,298
Management $5,144,632
Fundraising $0
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
84%
Meets
Compared with Baltimore peers
Measure
This organization
Peer median
Operating reserves
9.1 mo
27.1 mo
Typical margin
−15.3%
+27.2%
Spending growth
+6.6% / yr
+2.1% / yr
Debt load
34.6%
21.1%
Peers: the 4 Baltimore medical research organizations with a score, ranked or below the bar.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$28,903,115Fiscal year 2023
Expenses$31,448,930Fiscal year 2023
Total assets$36,656,603Fiscal year 2023
Total liabilities$12,690,938Fiscal year 2023
Fiscal year ending June2023
Revenue$28,903,115
Expenses$31,448,930
Net income−$2,545,815
Net assets$23,965,665
Notable sources of revenue
Percent of total revenue
Contributions
$26,098,672
90.3%
Program services
$1,749,804
6.1%
Investment income
$700,573
2.4%
Other (net)
$354,066
1.2%
Assets / debt
Total assets
$36,656,603
Total liabilities
$12,690,938
Net assets
$23,965,665
Compensation
Not in our extract for this year.
Fiscal year ending June2022
Revenue$22,894,222
Expenses$29,512,998
Net income−$6,618,776
Net assets$25,304,996
Notable sources of revenue
Percent of total revenue
Contributions
$16,080,378
70.2%
Program services
$2,921,001
12.8%
Investment income
$697,583
3.0%
Other (net)
$3,195,260
14.0%
Assets / debt
Total assets
$31,106,210
Total liabilities
$5,801,214
Net assets
$25,304,996
Compensation
Officers and key employees
$2,342,466
Share of expenses
7.9%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?